These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 26855028)

  • 21. Acute and Long-term Adverse Events Associated With Checkpoint Blockade.
    Davies M
    Semin Oncol Nurs; 2019 Oct; 35(5):150926. PubMed ID: 31514992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
    Braster R; O'Toole T; van Egmond M
    Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune checkpoint inhibitors renal side effects and management.
    Rassy EE; Kourie HR; Rizkallah J; Karak FE; Hanna C; Chelala DN; Ghosn M
    Immunotherapy; 2016 Dec; 8(12):1417-1425. PubMed ID: 28000536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know.
    Habre M; Habre SB; Kourie HR
    Immunotherapy; 2016 Dec; 8(12):1437-1446. PubMed ID: 28000535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel vaccines for glioblastoma: clinical update and perspective.
    Winograd EK; Ciesielski MJ; Fenstermaker RA
    Immunotherapy; 2016 Nov; 8(11):1293-1308. PubMed ID: 27993092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions.
    DiLillo DJ; Ravetch JV
    Cancer Immunol Res; 2015 Jul; 3(7):704-13. PubMed ID: 26138698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutrophils in antibody-based immunotherapy of cancer.
    van Egmond M
    Expert Opin Biol Ther; 2008 Jan; 8(1):83-94. PubMed ID: 18081538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy.
    King GT; Sharma P; Davis SL; Jimeno A
    Drugs Today (Barc); 2018 Feb; 54(2):103-122. PubMed ID: 29637937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors.
    Kottschade LA
    Curr Oncol Rep; 2018 Mar; 20(3):24. PubMed ID: 29511902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.
    Battella S; Cox MC; Santoni A; Palmieri G
    J Leukoc Biol; 2016 Jan; 99(1):87-96. PubMed ID: 26136506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Nonclinical Evaluation of Next-generation Therapeutic Monoclonal Antibodies].
    Ishii-Watabe A; Tada M; Suzuki T; Kawasaki N
    Yakugaku Zasshi; 2015; 135(7):857-66. PubMed ID: 26135085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
    Barbee MS; Ogunniyi A; Horvat TZ; Dang TO
    Ann Pharmacother; 2015 Aug; 49(8):907-37. PubMed ID: 25991832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune modulation in cancer with antibodies.
    Page DB; Postow MA; Callahan MK; Allison JP; Wolchok JD
    Annu Rev Med; 2014; 65():185-202. PubMed ID: 24188664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Toxicities of immune checkpoint inhibitors and their management].
    Kostine M; Marabelle A; Schaeverbeke T; Kfoury M
    Med Sci (Paris); 2019 Dec; 35(12):949-956. PubMed ID: 31903899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy.
    Houot R; Kohrt HE; Marabelle A; Levy R
    Trends Immunol; 2011 Nov; 32(11):510-6. PubMed ID: 21907000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy.
    Jiang CT; Chen KG; Liu A; Huang H; Fan YN; Zhao DK; Ye QN; Zhang HB; Xu CF; Shen S; Xiong MH; Du JZ; Yang XZ; Wang J
    Nat Commun; 2021 Mar; 12(1):1359. PubMed ID: 33649336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells.
    Marcucci F; Bellone M; Rumio C; Corti A
    MAbs; 2013; 5(1):34-46. PubMed ID: 23211740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints.
    Mirzaei R; Sarkar S; Yong VW
    Trends Immunol; 2017 Feb; 38(2):104-115. PubMed ID: 27964820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The microbiome in anti-cancer therapy.
    Bashiardes S; Tuganbaev T; Federici S; Elinav E
    Semin Immunol; 2017 Aug; 32():74-81. PubMed ID: 28431920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.